AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$PCVX

Cowan Elvia sold $183K of PCVX

Cowan Elvia (SVP, Finance & CAO) sold 3,000 shares of Vaxcyte, Inc. (PCVX) at an average of $60.92 ($60.76–$61.55, $0.18M total) across 2 trades on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cowan Elvia
Published Nov 4, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PCVX
Neutral
high confidence
Mentioned
$PCVX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXNeutralLow
01

Why it matters

The filing provides a factual update on insider holdings but carries little trading weight.

02

Market read

A routine insider sale with minimal market impact.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 3/10Timing: post‑market filing on 2026‑11‑04

Background

SEC Form 4 filing discloses insider transactions required by regulators.

Company-level read

Ticker impact

$PCVXNeutralHigh confidence
Context

SVP of Finance sold 3,000 shares for $182,753 via a 10b5‑1 plan, reducing holdings to 27,860 shares.

Expected impact

likely minimal pressure as the market prices in the modest sell‑off.

Evidence & confidence

The transaction size (~$0.18 M) is trivial relative to market cap; no material price move expected.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The sale could signal insider confidence if the 10b5‑1 plan was pre‑arranged and not market‑driven.

Key entities

  • Officer
    Cowan Elvia

    SVP, Finance & CAO at Vaxcyte, reporting the sale.

  • Company
    Vaxcyte, Inc.

    Biotech firm listed on NASDAQ under ticker PCVX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PCVX insider trading history →

Related articles

$PCVXHighAI 9/10

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety P

SEC EDGAR 8-K
$PCVXHighAI 8/10

Vaxcyte’s vaccine candidate met every main goal in a trial of 4,047 adults. More trial results are expected in 2027.

Vaxcyte's VAX-31 vaccine met all primary endpoints in a Phase 3 trial of 4,047 adults, showing safety and efficacy. The company plans to report more trial results in 2027 and submit a BLA in 2028. VAX-31 is designed to prevent pneumococcal disease. Vaxcyte also announced progress in its VAX-A1 vaccine candidate for Group A Streptococcus.

stocktitan.net
$PCVXHighAI 9/10

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte reported Q3 2026 results, highlighting positive topline data from the OPUS-1 Phase 3 trial of VAX-31, meeting all primary endpoints. The company expects results from OPUS-2 and OPUS-3 trials in early 2027, supporting a BLA submission in 2028. Vaxcyte also announced progress in its VAX-31 infant indication and VAX-A1 Phase 1 study. As of September 30, 2026, the company had $3.4 billion in cash and investments.

globenewswire.com